Risk of central nervous system versus systemic relapse in
patients with diffuse large B-cell lymphoma treated with
R-CHOP: What should we focus on?

J 2025

Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on?

KLANOVA, Magdalena; Samuel HRICKO; Michal MASAR; Prokop VODICKA; David ŠÁLEK et al.

Základní údaje

Originální název

Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on?

Autoři

Vydání

HemaSphere, Hoboken, Wiley, 2025, 2572-9241

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 14.600 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00142211

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

B-cell lymphoma; R-CHOP; central nervous system; systemic relapse

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 6. 10. 2025 10:46, Mgr. Tereza Miškechová

Anotace

V originále

Diffuse large B-cell lymphoma (DLBCL) is the most common hematological malignancy in adults. Although clinical outcomes of patients with DLBCL have improved over the past two decades, a significant proportion of DLBCL patients remain at risk of lymphoma relapse/progression or death due to relapse.1 Patients with high international prognostic index (IPI) or central nervous system IPI (CNS-IPI) scores face the greatest risks of systemic and CNS relapse. The CNS-IPI model has been validated in numerous studies and is widely used in clinical practice to guide decisions regarding CNS prophylaxis. However, the effectiveness of CNS prophylaxis has been repeatedly questioned in the recent retrospective studies focusing on both intrathecal (IT) and intravenous high-dose methotrexate (HD MTX). There is a lack of robust, prospective clinical trials evaluating the impact of CNS prophylaxis on the incidence of CNS relapse. As such, CNS prophylaxis may still be considered for high-risk patients, in accordance with international guidelines (NCCN v5.2025). However, patients classified as high-risk by IPI or CNS-IPI are at risk of not only CNS relapses but also systemic relapses. The risk proportion of these two types of relapse in the same patient population has not been formally studied to date. To address this, we analyzed the competing risks of systemic versus CNS relapse in a real-world cohort of patients with DLBCL.

Návaznosti

LM2023033, projekt VaV

Název: Síť českých biobank

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, BBMRI.cz - Síť českých biobank

Citovat

KLANOVA, Magdalena; Samuel HRICKO; Michal MASAR; Prokop VODICKA; David ŠÁLEK; Natasa KOPALOVA; Petra BLAHOVCOVA; Daniela KURUCZOVA; Katerina BENESOVA; Jozef MICHALKA; Jan KOREN; Pavel KLENER; Andrea JANÍKOVÁ a Marek TRNENY. Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on? HemaSphere. Hoboken: Wiley, 2025, roč. 9, č. 9, s. 1-4. ISSN 2572-9241. Dostupné z: https://doi.org/10.1002/hem3.70201.

@article{2523896,
   author = {Klanova, Magdalena and Hricko, Samuel and Masar, Michal and Vodicka, Prokop and Šálek, David and Kopalova, Natasa and Blahovcova, Petra and Kuruczova, Daniela and Benesova, Katerina and Michalka, Jozef and Koren, Jan and Klener, Pavel and Janíková, Andrea and Trneny, Marek},
   article_location = {Hoboken},
   article_number = {9},
   doi = {https://doi.org/10.1002/hem3.70201},
   keywords = {B-cell lymphoma; R-CHOP; central nervous system; systemic relapse},
   language = {eng},
   issn = {2572-9241},
   journal = {HemaSphere},
   title = {Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on?},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/hem3.70201},
   volume = {9},
   year = {2025}
}

TY  - JOUR
ID  - 2523896
AU  - Klanova, Magdalena - Hricko, Samuel - Masar, Michal - Vodicka, Prokop - Šálek, David - Kopalova, Natasa - Blahovcova, Petra - Kuruczova, Daniela - Benesova, Katerina - Michalka, Jozef - Koren, Jan - Klener, Pavel - Janíková, Andrea - Trneny, Marek
PY  - 2025
TI  - Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on?
JF  - HemaSphere
VL  - 9
IS  - 9
SP  - 1-4
EP  - 1-4
PB  - Wiley
SN  - 25729241
KW  - B-cell lymphoma
KW  - R-CHOP
KW  - central nervous system
KW  - systemic relapse
UR  - https://onlinelibrary.wiley.com/doi/10.1002/hem3.70201
N2  - Diffuse large B-cell lymphoma (DLBCL) is the most common hematological malignancy in adults. Although clinical outcomes of patients with DLBCL have improved over the past two decades, a significant proportion of DLBCL patients remain at risk of lymphoma relapse/progression or death due to relapse.1 Patients with high international prognostic index (IPI) or central nervous system IPI (CNS-IPI) scores face the greatest risks of systemic and CNS relapse. The CNS-IPI model has been validated in numerous studies and is widely used in clinical practice to guide decisions regarding CNS prophylaxis. However, the effectiveness of CNS prophylaxis has been repeatedly questioned in the recent retrospective studies focusing on both intrathecal (IT) and intravenous high-dose methotrexate (HD MTX). There is a lack of robust, prospective clinical trials evaluating the impact of CNS prophylaxis on the incidence of CNS relapse. As such, CNS prophylaxis may still be considered for high-risk patients, in accordance with international guidelines (NCCN v5.2025). However, patients classified as high-risk by IPI or CNS-IPI are at risk of not only CNS relapses but also systemic relapses. The risk proportion of these two types of relapse in the same patient population has not been formally studied to date. To address this, we analyzed the competing risks of systemic versus CNS relapse in a real-world cohort of patients with DLBCL.
ER  -

KLANOVA, Magdalena; Samuel HRICKO; Michal MASAR; Prokop VODICKA; David ŠÁLEK; Natasa KOPALOVA; Petra BLAHOVCOVA; Daniela KURUCZOVA; Katerina BENESOVA; Jozef MICHALKA; Jan KOREN; Pavel KLENER; Andrea JANÍKOVÁ a Marek TRNENY. Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on? \textit{HemaSphere}. Hoboken: Wiley, 2025, roč.~9, č.~9, s.~1-4. ISSN~2572-9241. Dostupné z: https://doi.org/10.1002/hem3.70201.

Přehled o publikaci